An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies
Doris Giess, Judit Erdos, Claudia Wild
Topics & Concepts
Spinal muscular atrophyMedicineSMA*AtrophyPhysical medicine and rehabilitationPhysical therapyInternal medicineDiseaseCombinatoricsMathematicsNeurogenetic and Muscular Disorders ResearchCraniofacial Disorders and TreatmentsSpinal Dysraphism and Malformations